Category: Include on Menu
-
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates
Editas Medicine Inc. (NASDAQ:EDIT) reported fourth-quarter results that came in ahead of analyst expectations, with the gene-editing company posting a smaller-than-expected loss and stronger revenue. The company reported a loss of $0.06 per share, beating the consensus estimate for a $0.23 loss. Revenue totaled $24.74 million, well above the analyst forecast of $8.02 million, although…
-
BETA Technologies shares slide as wider loss overshadows strong revenue growth
BETA Technologies, Inc. (NYSE:BETA) reported fourth-quarter revenue of $11.1 million on Monday, representing a 151% increase from $4.4 million in the same period a year earlier. However, the electric aerospace company posted a larger-than-expected loss, with adjusted earnings per share of -$2.02 for the quarter ended December 31, 2025. The company’s shares dropped 2.91% in…
-
Heritage Insurance shares climb more than 5% after strong Q4 earnings beat
Heritage Insurance Holdings, Inc. (NYSE:HRTG) reported fourth-quarter results on Monday that came in ahead of analyst expectations, supported by stronger underwriting results and significantly lower catastrophe-related losses. Following the announcement, the insurer’s shares gained 5.62% in pre-market trading. The property and casualty insurance company posted adjusted earnings per share of $2.15 for the quarter, far…
-
Aureus Greenway shares jump on planned drone merger backed by Trump family
Shares of Aureus Greenway Holdings (NASDAQ:AGH) surged 55% after The Wall Street Journal reported that the company plans to merge with drone manufacturer Powerus, which is supported by investments tied to President Trump’s sons. According to the report, Eric Trump and Donald Trump Jr. are backing Powerus through their investment firm American Ventures. The transaction…
-
Korn Ferry shares drop nearly 5% despite earnings beat as guidance tempers outlook
Korn Ferry (NYSE:KFY) reported third-quarter results on Monday that came in above Wall Street expectations but issued a cautious outlook for the upcoming quarter. Shares of the global consulting firm declined 4.73% in pre-market trading following the announcement, as investors reacted to the company’s guarded guidance. For the third quarter, Korn Ferry posted adjusted earnings…
-
Hims surges 44% after report Novo Nordisk may offer weight-loss drugs on its platform
Novo Nordisk (NYSE:NVO) is planning to distribute its weight-loss medications through the telehealth platform operated by Hims & Hers Health (NYSE:HIMS), signaling an unexpected thaw in relations between the companies after a recent legal clash, Bloomberg reported over the weekend. Shares of Hims — which have fallen roughly 51% so far this year — jumped…
-
Short bets on U.S. ETFs post biggest weekly increase since Liberation Day
Short interest in U.S.-listed exchange-traded funds rose sharply last week, climbing 8.3% and marking the largest weekly increase since Liberation Day as well as the second-largest jump seen in the past five years, according to figures from the Goldman Sachs Prime Trading Desk. The surge suggests a notable rise in hedging activity, the team led…
-
Yardeni warns meltdown risk rising as Polymarket recession odds climb to 37%
Expectations of a U.S. recession have risen notably since the escalation of conflict in the Middle East, as investors grow more concerned about the economic consequences of higher energy prices and geopolitical instability. U.S. stock futures were lower in early Monday trading, with S&P 500 futures declining 1.4%. Data from prediction platform Polymarket shows the…
-
Live Nation nears settlement in U.S. antitrust case without selling Ticketmaster, report says
Live Nation Entertainment (NYSE:LYV) is reportedly approaching a settlement with U.S. regulators in a federal antitrust lawsuit that could allow the company to keep its Ticketmaster division, according to a Bloomberg News report on Monday citing people familiar with the matter. The U.S. Department of Justice and more than two dozen states filed the lawsuit…
-
Agilent to buy Biocare Medical for $950 million in cash
Agilent Technologies (NYSE:A) announced Monday that it has agreed to acquire privately held clinical pathology company Biocare Medical in an all-cash transaction valued at $950 million. The life sciences company said it will purchase California-based Biocare Medical from private equity firms Excellere Partners and GHO Capital Partners, with the transaction expected to close by the…